Today: August 19, 2018, 9:17 pm
  
Health

Cystic Fibrosis: Disease Insights and Market Forecasts to 2024 by Pharmascroll

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Cystic Fibrosis disease with a forecast till 2024
Pharmascroll Research and Consulting Private Limited
Pharmascroll Research and Consulting Private Limited
PR-Inside.com: 2018-05-15 08:39:56
“Cystic Fibrosis: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Cystic Fibrosis disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Cystic Fibrosis, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.


Geographies covered:

US

Germany

France

Italy

Spain

UK

Japan

Australia

Canada

Drugs covered

Orkambi

Pulmozyme

Kalydeco

Symdeko (Tezacaftor + Ivacaftor)

Tobramycin

VX-659 + Tezacaftor + Ivacaftor

VX-152 + Tezacaftor + Ivacaftor

VX-440 + Tezacaftor + Ivacaftor

QR-010

ABBV-2222

GLPG1837

Disease Indication Overview:

This section of the report gives the overview of Cystic Fibrosis disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Cystic Fibrosis disease. Further details on the profile of Cystic Fibrosis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Cystic Fibrosis disease.

Epidemiology Forecasts to 2024:

This section of the report provides the overview of Cystic Fibrosis diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in Cystic Fibrosis disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in Cystic Fibrosis disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the Cystic Fibrosis market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

Drugs and Market Forecast to 2024:

The report in its last section provides sales and patient numbers forecast for the overall Cystic Fibrosis market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

Why Purchase the Report:

• Robust Market and Drug forecast available at country level

• Forecast in terms of both $ sales and Patient Numbers

• Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool

• Detailed Drug Attribute analysis on multiple Clinical Parameters

• Multiple Countries coverage

• Current Marketed and Pipeline Drugs coverage

• Detailed Disease Insights coverage

To read more about the report please visit pharmascroll.com/cystic-fibrosis-disease-insights-and-market-for ..

To enquire about the report or to make a purchase for the report please write to enquiry@pharmascroll.com

Press Information
Pharmascroll Research and Consulting Private Ltd
Hi Tech City

Hyderabad

India

Zip- 500084

Bhawna Gupta
Consultant
+919776868067
email
pharmascroll.com/cystic-fibrosis-disease-insights-and-market-for ..


# 608 Words
Related Articles
More From The Author
Pharmascroll launches Market intelligence reports on [..]
Pharmascroll, a Pharmaceutical market research and business consulting firm, would be offering Monthly Market Intelligence reports [..]
PPMS and SPMS: Epidemiology and Market Forecasts [..]
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves [..]
 
More From Health
Drug Abuse Treatment Market to Surpass US$ [..]
(EMAILWIRE.COM, August 06, 2018 ) Global Drug Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, [..]
Sponsors Recommend Novotech for CRO Leadership Award
SYDNEY, Aug 9, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech has been awarded the "Exceeded Customer Expectations" [..]
Nurse Staffing Agency Website Focuses on Services; [..]
Elkhart, IN; August 1, 2018 – Excellent Nursing Services, Inc. (ENS) has announced the launch of the agency’s website highlighting [..]
Ascletis-developed Ganovo Acquired Extraordinary Achievement
Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association HONG [..]
Primary Sclerosing Cholangitis Market to Reach US$ [..]
(EMAILWIRE.COM, July 30, 2018 ) Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.